The miR Sentinel Prostate Cancer Test is a non-invasive molecular test based on the analysis of small non-coding RNAs (sncRNA) isolated from non-DRE urinary exosomes. It provides an innovative...
Read More »miR Scientific to evaluate impact and deployment of its prostate cancer liquid biopsy test in Puerto Rico
miR Scientific and Puerto Rico government announce pioneering cooperation agreement to evaluate impact and deployment of its prostate cancer liquid biopsy test in Puerto Rico miR Scientific, LLC, a...
Read More »miR Scientific announces FDA breakthrough device designation for its prostate cancer liquid biopsy test
miR Scientific, LLC, a healthcare company whose purpose is to transform global cancer management by providing early and highly accurate detection, characterization and monitoring of disease, announced...
Read More »Urinary exosome based, non-invasive prostate cancer test validated
miR Scientific, LLC, a healthcare company whose purpose is to transform cancer management by providing early and highly accurate detection, characterization and monitoring of disease, today announced the publication of validation data...
Read More »miR Scientific presents a new non-invasive test for identifying clinically significant prostate cancer
miR Scientific LLC, a precision bioscience company focused on comprehensive disease detection and management, presented, “miR Scientific Sentinel Scores™ – a new platform technology for identification...
Read More »